121 related articles for article (PubMed ID: 38529769)
1. Dosimetry during iodine-131 therapy - a technical point of view from a single centre's own experience.
Chalewska W; Cegla P; Moczulska A; Strzemecka E; Sackiewicz A; Dedecjus M
Nucl Med Rev Cent East Eur; 2024; 27(0):1-5. PubMed ID: 38529769
[TBL] [Abstract][Full Text] [Related]
2. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
Med Phys; 2016 Oct; 43(10):5279-5287. PubMed ID: 28105713
[TBL] [Abstract][Full Text] [Related]
3. Differentiated thyroid carcinoma: Incremental diagnostic value of
Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
[TBL] [Abstract][Full Text] [Related]
4. I-131 SPECT/CT elucidates cryptic findings on planar whole-body scans and can reduce needless therapy with I-131 in post-thyroidectomy thyroid cancer patients.
Blum M; Tiu S; Chu M; Goel S; Friedman K
Thyroid; 2011 Nov; 21(11):1235-47. PubMed ID: 22007920
[TBL] [Abstract][Full Text] [Related]
5. Comparative Study of Initial Post-Therapeutic
Dai H; Qi Z; Huang S; Qi M; Huang R
Endocr Pract; 2023 Feb; 29(2):97-103. PubMed ID: 36356838
[TBL] [Abstract][Full Text] [Related]
6. [Impact of 131I SPECT/CT on the management of differentiated thyroid carcinoma outpatients with radioablation].
Mizokami D; Kosuda S; Shiotani A; Kinoshita F; Saotome K; Morozumi K
Nihon Jibiinkoka Gakkai Kaiho; 2014 May; 117(5):673-80. PubMed ID: 24956745
[TBL] [Abstract][Full Text] [Related]
7. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
Med Phys; 2016 Oct; 43(10):5279. PubMed ID: 27782699
[TBL] [Abstract][Full Text] [Related]
8. High Level of Agreement Between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases.
Ruhlmann M; Jentzen W; Ruhlmann V; Pettinato C; Rossi G; Binse I; Bockisch A; Rosenbaum-Krumme S
J Nucl Med; 2016 Sep; 57(9):1339-42. PubMed ID: 27151981
[TBL] [Abstract][Full Text] [Related]
9. 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer.
Freudenberg LS; Jentzen W; Marlowe RJ; Koska WW; Luster M; Bockisch A
Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):690-3. PubMed ID: 18058605
[TBL] [Abstract][Full Text] [Related]
10. Clinical Implications of Adding SPECT/CT to Radioiodine Whole-Body Scan in Patients With Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis.
Chong A; Seo Y; Bang JI; Park S; Kim K; Hong CM; Choi M; Oh SW; Lee SW
Clin Nucl Med; 2024 Mar; 49(3):215-225. PubMed ID: 38048517
[TBL] [Abstract][Full Text] [Related]
11. Head-to-Head Comparison of
Pitalua-Cortes Q; García-Perez FO; Vargas-Ahumada J; Gonzalez-Rueda S; Gomez-Argumosa E; Ignacio-Alvarez E; Soldevilla-Gallardo I; Torres-Agredo L
Front Endocrinol (Lausanne); 2021; 12():794759. PubMed ID: 35002972
[TBL] [Abstract][Full Text] [Related]
12. Clinical applications of single-photon emission computed tomography/computed tomography in post-ablation
Jiang L; Xiang Y; Huang R; Tian R; Liu B
Pediatr Radiol; 2021 Aug; 51(9):1724-1731. PubMed ID: 33759024
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes and prognostic factors of radioiodine ablation therapy for lymph node metastases from papillary thyroid carcinoma.
Wu X; Gu H; Gao Y; Li B; Fan R
Nucl Med Commun; 2018 Jan; 39(1):22-27. PubMed ID: 29135721
[TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Diagnostic Value of SPECT/CT Imaging in Post-radioiodine Therapy in Thyroid Cancer.
Al Hatmi A; Jain A; Mittal AK; Hussain S
Sultan Qaboos Univ Med J; 2022 Feb; 22(1):74-81. PubMed ID: 35299812
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer.
Shankar LK; Yamamoto AJ; Alavi A; Mandel SJ
J Nucl Med; 2002 Jan; 43(1):72-6. PubMed ID: 11801706
[TBL] [Abstract][Full Text] [Related]
17. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer.
Grewal RK; Tuttle RM; Fox J; Borkar S; Chou JF; Gonen M; Strauss HW; Larson SM; Schöder H
J Nucl Med; 2010 Sep; 51(9):1361-7. PubMed ID: 20720058
[TBL] [Abstract][Full Text] [Related]
18. Role of Diagnostic
Spanu A; Nuvoli S; Gelo I; Mele L; Piras B; Madeddu G
J Nucl Med; 2018 Oct; 59(10):1510-1515. PubMed ID: 29496990
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I.
Pettinato C; Monari F; Nanni C; Allegri V; Marcatili S; Civollani S; Cima S; Spezi E; Mazzarotto R; Fanti S
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):509-14. PubMed ID: 23358403
[TBL] [Abstract][Full Text] [Related]
20. Pretherapeutic dosimetry in patients affected by metastatic thyroid cancer using 124I PET/CT sequential scans for 131I treatment planning.
Pettinato C; Spezi E; Nanni C; Grassetto G; Monari F; Allegri V; Civollani S; Cima S; Zagni P; Mazzarotto R; Colletti PM; Rubello D; Fanti S
Clin Nucl Med; 2014 Aug; 39(8):e367-74. PubMed ID: 24978332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
